Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 84, Issue 2, Pages 149-160Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2012.02.012
Keywords
Non-small cell lung cancer; VEGF; bFGF; Angiogenic markers; Expression; Prognostic impact; Review
Categories
Ask authors/readers for more resources
Despite major advances in cancer therapeutics, the prognosis for lung cancer patients is still poor and the median survival for patients presenting with advanced non-small cell lung cancer (NSCLC) is only 8-10 months. Angiogenesis is an important biological process and a relatively early event during lung cancer pathogenesis. Anti-angiogenic agents are used in treating patients with NSCLC, and their molecular biomarkers are also being assessed to predict response. A better understanding of the biology of angiogenesis in NSCLC may reveal new targets for treating this malignancy. In this article, we review the expression and prognostic impact of the angiogenic growth factors, vascular endothelial growth factor and basic fibroblast growth factor, in NSCLC. (C) 2012 Published by Elsevier Ireland Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available